ASTRAZENECA PHARMA share price has plunged 7% and is presently trading at Rs 6,562.0.
Meanwhile, the BSE HEALTHCARE index is at 40,926.1 (up 0.2%).
Among the top losers in the BSE HEALTHCARE index today are CAPLIN POINT (down 6.6%) and FDC (down 3.7%).
ALKEM LABORATORIES (up 3.6%) and ERIS LIFESCIENCES (up 3.3%) are among the top gainers today.
Over the last one year, ASTRAZENECA PHARMA has moved up from Rs 3,810.8 to Rs 6,562.0, registering a gain of Rs 2,751.2 (up 72.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 40,926.1, registering a gain of 44.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 115.2%), GSK Pharma (up 105.8%) and SUVEN PHARMACEUTICALS (up 104.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,886.2 (down 0.7%).
The top losers among the BSE Sensex today are Asian Paints (down 3.6%) and Infosys (down 2.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,098.7 (down 0.8%). LTIMINDTREE and Grasim Industries are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 78,886.2, registering a gain of 12,932.7 points (up 19.6%).
ASTRAZENECA PHARMA net profit grew 128.6% YoY to Rs 395 million for the quarter ended March 2024, compared to a profit of Rs 173 million a year ago. Net sales rose 34.6% to Rs 3,832 million during the period as against Rs 2,847 million in January-March 2023.
For the year ended March 2024, ASTRAZENECA PHARMA reported 62.7% increase in net profit to Rs 1,615 million compared to net profit of Rs 993 million during FY23. Revenue of the company grew 29.2% to Rs 12,955 million during FY24.
The current Price to earnings ratio of ASTRAZENECA PHARMA, based on rolling 12 month earnings, stands at 101.6.
Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA Plunges 7%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!